These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38772345)

  • 1. Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study.
    Friedland R; Glick M; Amitay-Laish I; Toledano H
    Dermatology; 2024; 240(4):565-571. PubMed ID: 38772345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study.
    Boull CL; Gardeen S; Abdali T; Li E; Potts J; Rubin N; Carlberg VM; Gupta D; Hunt R; Luu M; Maguiness SM; Moertel CL; Song H; Vivar KL; Coughlin C; Huang JT; Lara-Corrales I
    J Am Acad Dermatol; 2021 Jun; 84(6):1554-1561. PubMed ID: 32682884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
    Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
    Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
    Boull C; Hook K; Moertel C; Maguiness S
    Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
    Lacroix JP; Wang B
    J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
    Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
    Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
    N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors.
    Reinhard R; Gebhardt C; Schmieder A; Umansky V; Utikal J
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e375-e377. PubMed ID: 28222227
    [No Abstract]   [Full Text] [Related]  

  • 16. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
    Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study.
    Song H; Zhong CS; Kieran MW; Chi SN; Wright KD; Huang JT
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27682. PubMed ID: 30821092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.